Beta-adrenoceptor blocking drugs can be characterised by their pharmacokinetic properties.
One of the most important factors appears to be lipid solubility. Lipophilic beta-adrenoceptor …

The β-adrenoceptor antagonists have been widely used clinically for over 20 years and their
pharmacokinetics have been more thoroughly investigated than any other group of drugs …

A great number of beta-adrenoceptor blocking drugs are now available for clinical use which
show great differences with respect to their pharmacokinetic properties. Bioavailability might …

All β-adrenoreceptor blocking drugs seem to be fairly rapidly and completely absorbed from
the gastro-intestinal tract. The rate of absorption, however, appears to be lower in elderly …

Many beta-adrenoceptor-blocking agents are well studied today. They difer from one
another not only in their pharmacologic profiles (cardioselectivity, intrinsic sympathomimetic …

Quite a number of j3-adrenoceptor-blocking drugs are available today for the treatment of
hypertension and other cardiovascular disorders. Since ß-blockers are drugs which are …

Beta adrenoceptor blocking drugs are all competitive inhibitors of the beta receptor although
they may or may not possess, beta 1-(cardio) selectivity, intrinsic sympathomimetic activity …

Summary β-Adrenergic blockade has provided one of the major pharmacotherapeutic
advances of this century. The drugs in this class have the common property of blocking the …

Currently there are nine 8-adrenoceptor blocking drugs and one a/,!?-blocker available for
clinical use in the UK The pharmacokinetics of the group vary significantly from one member …

J Clin Bas Cardiol 1998; 1: 5 β-adrenoceptor blocking drugs are widely used for the
treatment of cardiovascular diseases such as arterial hypertension, coronary heart disease …